CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (156,847,565)	$ (99,997,414)
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities	49,774,638	35,567,205
Warrant related expense		7,649,395
Depreciation and amortization	940,272	633,079
Loss on induced exchanges of debt	13,005,329
Amortization of deferred revenue	(77,298)	(43,230)
Amortization of bond premiums		205,071
Amortization of debt issuance costs	1,552,785	547,366
Amortization of deferred rent	169,828	18,062
(Gain) loss on sale of marketable securities		15,682
Increase (decrease) in allowance for doubtful accounts	(7,430)	(52,561)
Other	(296,096)	467,340
Non-cash expense related to stock compensation	2,673,184	2,593,085
Changes in operating assets and liabilities:
Accounts receivable – net of reserve	293,677	(306,795)
Other receivables	(30,000)	125,578
Inventories – net of reserve	580,016	(335,091)
Other current assets	(5,458,212)	43,467
Prepaid expenses	(3,384,850)	274,515
Accounts payable and accrued expenses	(9,467,734)	4,409,509
Accrued interest on non-recourse debt	10,626,390
Net cash used in operating activities	(95,953,066)	(48,185,737)
Cash flows from investing activities:
Purchases of marketable securities	(10,380,182)	(29,160,546)
Proceeds from sales/maturities of marketable securities	69,841,996	42,240,521
Purchases of property and equipment	(4,929,765)	(829,325)
Net cash provided by investing activities	54,532,049	12,250,650
Cash flows from financing activities:
Sale of common stock and warrants, net of related expenses	123,508,937	43,278,473
Exercise of stock options and warrants	997,208	1,812,780
Proceeds from the issuance of non-recourse debt	182,217,000
Debt conversion fees	(530,064)
Tax withholding payments for stock compensation	(1,523,183)	(448,625)
Net cash provided by financing activities	304,669,898	44,642,628
Effect of changes in exchange rates on cash and cash equivalents	103,816	(12,698)
Net increase in cash and cash equivalents	263,352,697	8,694,843
Cash and cash equivalents beginning of period	43,393,570	13,203,625
Cash and cash equivalents end of period	306,746,267	21,898,468
Supplemental disclosure of cash flow information:
Interest paid	2,850,000	$ 4,750,000
Schedule of non-cash investing and financing activities:
Convertible Senior Notes converted to common stock	80,000,000
Accrued capital expenditures	1,439,090
Reclass of warrant liability to capital contributed in excess of par	$ 70,149,633